Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in lymphopenic sepsis
NCT03821038Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of efineptakin alfa in sepsis (2 arms), sponsored by RevImmune. Primary endpoint: Lymphocyte reconstitution at Day 29. Started Jun 2019; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT03821038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821038.